Zacks Investment Research downgraded shares of ENTEROMEDICS IN (ETRM) from OUTPERFORM to NEUTRAL on January 02, 2015, with a target price of $1.60.
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ENTEROMEDICS IN (ETRM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment